Emgality (Galcanezumab)

Description

Emgality (Galcanezumab) – Once-Monthly Injectable for Migraine Prevention and Episodic Cluster Headache

Struggling with frequent migraines that disrupt your life? Emgality (galcanezumab-gnlm) is an FDA-approved CGRP monoclonal antibody designed specifically for the preventive treatment of migraine in adults. Whether you experience episodic or chronic migraines (with 4 or more migraine days per month), Emgality helps reduce the frequency and severity of attacks so you can reclaim more migraine-free days.

Emgality works by targeting calcitonin gene-related peptide (CGRP), a key protein involved in migraine pain pathways. By blocking CGRP, this innovative biologic helps prevent migraines from starting rather than just treating them after they begin. Clinical studies showed that many patients experienced a significant reduction in monthly migraine headache days—often 4–5 fewer days per month compared to placebo— with some achieving a 50% or greater reduction.

Key Benefits of Emgality for Migraine Prevention

• Convenient once-monthly dosing — After an initial loading dose of 240 mg (two 120 mg injections), you only need one 120 mg subcutaneous injection per month.
• Self-administration at home — Use the easy-to-use prefilled pen or prefilled syringe in the abdomen, thigh, upper arm, or buttocks.
• Proven efficacy — Helps reduce migraine frequency, severity, and the need for acute rescue medications.
• Also approved for episodic cluster headache — Provides targeted relief with 300 mg (three 100 mg injections) at the start of a cluster period, then monthly until the period ends.

Many patients report noticeable improvements within the first month, with continued benefits over time. Emgality offers a modern, targeted approach for those who haven’t found sufficient relief with traditional oral preventives.

How to Use Emgality

• Migraine prevention dosing: Start with a 240 mg loading dose (two consecutive 120 mg injections), followed by 120 mg once monthly.
• Administration tips: Allow the pen or syringe to reach room temperature for 30 minutes before injecting. Do not shake or freeze. It’s designed for patient self-injection after proper training.
• Available as single-dose prefilled pens (120 mg/mL) or syringes (100 mg/mL or 120 mg/mL).

Important Safety Information

Emgality is generally well-tolerated, but the most common side effects are injection site reactions (such as pain, redness, itching, or swelling). Serious hypersensitivity reactions are rare but possible—discontinue use and seek medical help if they occur. It is not known if Emgality is safe during pregnancy or breastfeeding. Always consult your healthcare provider to determine if Emgality is right for you, especially if you have a history of allergic reactions.

Emgality is a prescription medication indicated only for adults. It is not for use in children, and safety in patients 65+ has not been extensively studied.

Why Choose Emgality for Migraine Relief?

If you’re tired of daily migraines interfering with work, family, and daily activities, Emgality offers a science-backed, monthly solution that targets the root cause with CGRP inhibition. Talk to your doctor or neurologist today about whether this preventive migraine treatment could help you experience more pain-free days.

Important: This description is for informational purposes only and is not a substitute for professional medical advice. Full prescribing information and patient labeling should be reviewed with your healthcare provider. Individual results may vary.